Redcare Pharmacy (Shop Apoth) stock: Q1 revenue up 18% as adjusted EBITDA jumps 58% on strong topline growth (NL0012044747)

Redcare Pharmacy reports first-quarter 2026 revenue growth of 18.4% year over year and a 58% increase in adjusted EBITDA, highlighting continued momentum in its European online pharmacy business.

Redcare Pharmacy has reported a strong start to 2026, with first?quarter group revenue up 18.4% year over year and adjusted EBITDA rising 58% on a comparable basis, according to its latest quarterly update. The Netherlands?listed online pharmacy retailer, formerly known as Shop Apotheke Europe, posted sales of about EUR 849.5 million in the three months ended March 31, 2026, versus EUR 717.3 million in the same period a year earlier, while its net loss narrowed slightly to EUR 10.5 million from EUR 10.8 million. The results reflect continued growth in active customers and order volumes across its core German and European markets, even as the company navigates tight regulatory and margin environments in the pharmacy sector. EQS News as of 05/09/2026Marketscreener as of 05/09/2026

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Redcare Pharmacy N.V.
• Sector/industry: Healthcare, online pharmacy and mail?order retail
• Headquarters/country: Sevenum, Netherlands
• Core markets: Germany, Austria, Switzerland, France, Belgium, the Netherlands and other European countries
• Key revenue drivers: Prescription and over?the?counter medicines, health and beauty products, and related digital services
• Home exchange/listing venue: Euronext Amsterdam (ticker: RDC), with secondary listing on Xetra (ticker: RDC)
• Trading currency: Euro (EUR)

Redcare Pharmacy: core business model

Redcare Pharmacy operates as a leading European online pharmacy and mail?order retailer, offering prescription and non?prescription medicines, health and beauty products, and related digital services through its e?commerce platforms. The company serves consumers in multiple European countries, with Germany as its largest market, and positions itself as a digital?first alternative to traditional brick?and?mortar pharmacies. Its business model combines e?commerce logistics, regulatory compliance in highly controlled pharmacy markets, and customer?centric digital tools such as online consultations, medication reminders and personalized health content. Redcare Pharmacy official site as of 05/09/2026

The company’s operations are built around a centralized logistics and fulfillment infrastructure, which allows it to ship medicines and health products directly to consumers while adhering to strict pharmaceutical regulations. Redcare Pharmacy also partners with healthcare professionals and insurers in some markets to integrate its services into broader digital health ecosystems. This model supports recurring customer relationships, as many users rely on the platform for repeat prescriptions and chronic?care products, which can help stabilize order volumes even in competitive pricing environments. Redcare Pharmacy official site as of 05/09/2026

Main revenue and product drivers for Redcare Pharmacy

Redcare Pharmacy’s revenue is driven primarily by sales of prescription (Rx) and over?the?counter (non?Rx) medicines, complemented by health and beauty products and related services. In the first quarter of 2026, group revenue rose 18.4% year over year to about EUR 849.5 million, reflecting higher order volumes and an expanding active customer base. The company reported around 14.2 million active customers at the end of Q1 2026, up roughly 1.1 million from the prior?year quarter, indicating continued user acquisition and retention despite intense competition in the online pharmacy space. EQS News as of 05/09/2026Financial Engineering as of 05/09/2026

Within this mix, prescription medicines typically carry lower but regulated margins, while non?prescription products and health?related goods face more aggressive pricing competition. The company’s adjusted EBITDA growth of 58% in Q1 2026 suggests that operational efficiencies, scale benefits and cost discipline are helping to offset margin pressure in some segments. However, analysts note that the business remains exposed to regulatory changes, reimbursement policies and customer?acquisition costs, which can influence profitability even as top?line growth remains robust. EQS News as of 05/09/2026Financial Engineering as of 05/09/2026

Industry trends and competitive position

The European online pharmacy market is still relatively underpenetrated compared with other e?commerce segments, which leaves room for further growth but also attracts new entrants and pricing pressure. Redcare Pharmacy, as the German market leader in online pharmacy, benefits from brand recognition, an established logistics network and a large active customer base. At the same time, the sector faces structural challenges, including capped or tightly regulated margins on prescription drugs, intense competition in non?prescription categories and ongoing scrutiny from regulators and traditional pharmacy associations. Financial Engineering as of 05/09/2026

For US investors, Redcare Pharmacy offers exposure to the broader digital health and e?pharmacy trend, albeit via a European?listed vehicle. The company’s performance can serve as a proxy for how online pharmacy models scale in highly regulated healthcare markets, which may inform expectations for similar digital?health plays in the United States. However, investors should also consider currency risk, regulatory differences and the company’s dependence on European healthcare frameworks when assessing its long?term prospects. Redcare Pharmacy official site as of 05/09/2026

Conclusion

Redcare Pharmacy’s first?quarter 2026 results highlight solid top?line growth and a significant improvement in adjusted EBITDA, underscoring the momentum in its European online pharmacy business. Revenue of about EUR 849.5 million and a 58% year?over?year increase in adjusted EBITDA suggest that the company is leveraging scale and operational efficiencies, even as it operates in a highly regulated and competitive environment. The expansion of its active customer base to around 14.2 million users further supports the view that digital pharmacy adoption continues to rise in key European markets. EQS News as of 05/09/2026Financial Engineering as of 05/09/2026

For US investors, the stock offers indirect exposure to the digital health and e?pharmacy theme, but it also comes with European?specific regulatory, reimbursement and competitive risks. The company’s ability to maintain or expand margins in a low?pricing?power environment, manage customer?acquisition costs and adapt to evolving healthcare policies will be key determinants of its long?term performance. As with any equity investment, potential investors should weigh these factors against their own risk tolerance and diversification goals. Redcare Pharmacy official site as of 05/09/2026

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.